Document:

Exhibit 4.14

 

Form 51-102F3

MATERIAL CHANGE REPORT

 

	Item 1.	Name and Address of Reporting Issuer
	 	 
	 	Emerald Health Therapeutics, Inc. (the “Company”)
	 	PO Box 24076, 4420 West Saanich Road
	 	Victoria, British Columbia V8Z 7E7
	 	 
	Item 2.	Date of Material Change
	 	 
	 	November 28, 2018
	 	 
	Item 3.	News Release
	 	 
	 	A news release was disseminated on November 28, 2018 through GlobeNewswire and subsequently filed on SEDAR.
	 	 
	Item 4.	Summary of Material Changes
	 	 
	 	The Company announced the resignation of Chris Wagner as Chief Executive Officer and the appointment of Avtar Dhillon as President.
	 	 
	Item 5.	Full Description of Material Change 
	 	 
	 	Please see attached Schedule "A".
	 	 
	Item 6.	Reliance on subsection 7.1(2) of National Instrument 51-102 Not applicable.
	 	 
	Item 7.	Omitted Information
	 	 
	 	Not applicable.
	 	 
	Item 8.	Executive Officer
	 	 
	 	For further information, please contact: 
	 	Avtar Dhillon
	 	President and Executive Chairman 
	 	Telephone: 1.800.757.3536 ext.720
	 	 
	Item 9.	Date of Report
	 	 
	 	December 4, 2018

 

     

     

    

 

Schedule 'A'

 

 

Emerald Health Therapeutics Announces
Executive Chairman Avtar Dhillon

 Appointed as President; CEO Chris Wagner Steps Down

 

VICTORIA, British Columbia, Nov. 28, 2018
— Emerald Health Therapeutics, Inc. (“Emerald” or the “Company”) (TSXV:EMH; OTCQX:EMHTF) announced
today that Dr. Avtar Dhillon, Executive Chairman, has been appointed President of Emerald and that Chris Wagner has stepped down
as CEO.

 

“Emerald’s board of directors
thanks Chris for his numerous contributions during this period of rapid growth and wishes him well in his future endeavours,”
said Jim Heppell, a director of Emerald. “Emerald has now laid the groundwork for very rapid future growth. As Executive
Chairman, Dr. Dhillon has been intimately involved in setting the Company’s strategy and overseeing its operations. Under
his experienced stewardship, we expect Emerald to rapidly advance its differentiated business plan.”

 

Dr. Avtar Dhillon said, “Our plan
is to build on the momentum of, and accelerate, our foray into the world cannabis arena and leverage our asset base to maximize
our opportunities not only in Canada, but globally. Our goal is to be a preeminent player on the global stage, with science-backed
innovative cannabinoid products. As such, we are finalizing our expansive relationship with the Factors Group, which, when complete,
is expected to provide industrial-scale extraction, encapsulation, packaging, and distribution capability. We intend to feed this
processing capability with supply from our Pure Sunfarms joint venture, our Quebec facility, and hemp to be obtained through our
supply agreement.”

 

Dr. Dhillon is a life sciences entrepreneur
with more than 35 years of experience. He is CEO of Emerald Health Sciences, a major shareholder of the Company, and serves as
a board member and chairman of several life science companies. He is also Chairman of the Cannabis Canada Council. As a founder/co-founder
of many life science companies, he has raised more than $1B in public and private financings. As President and CEO of Inovio Pharmaceuticals,
Inc., Dr. Dhillon led a turnaround with multiple successful financings and licensing deals with Merck, Wyeth (now Pfizer) and Roche.
Before joining Inovio, he was Vice President of MDS Capital Corp. (now Lumira Capital Corp.). Prior to his business career, Dr.
Dhillon practiced family medicine. He has a BSc (Honours) in Human Physiology and an MD from the University of British Columbia.

 

Emerald would also like to announce the
departure of Paul Dillman as Executive Vice President of Global Sales and Marketing of the Company, effective as of November 22,
2018. The board also thanks Mr. Dillman for his service.

 

About Emerald Health Therapeutics, Inc.

 

Emerald Health Therapeutics, Inc. (TSXV:
EMH; OTCQX: EMHTF; Frankfurt: TBD) is a Canadian licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint venture in BC
is completing a sophisticated 1.1 million square feet greenhouse and its Agro-Biotech operation in Québec is completing
a 75,000 square feet indoor facility. Commercial production is expanding in both facilities. Emerald has secured approximately
500 acres of hemp harvest in 2018 and has contracted for approximately 1000 acres in 2019 to 2022 with the goal of extracting low-cost
cannabidiol (CBD). Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business,
and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Emerald
is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical
products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.

 

Please visit www.emeraldhealth.ca for more information
or contact:

 

Rob Hill, Chief Financial Officer

(800) 757 3536 Ext. #5

 

Ray Lagace, Investor Relations Manager

(800) 757 3536 Ext. #5

invest@emeraldhealth.ca

 

Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.

 

Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are
subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual
results or events could differ materially from our expectations expressed in or implied by such forward-looking statements. Such
statements include production capacity of various facilities; expansion of facilities; increased commercial production; anticipated
production costs; completion of the strategic relationship with Factors Group; implementation of future business plans; and receipt
of hemp deliveries.

 

     

     

    

 

Actual results may vary from forward-looking
statements. We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue
reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among
other things, failure to obtain regulatory approvals; failure to settle final documentation; failure to obtain necessary financing;
results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs;
demand for labour; demand for products; future distribution agreements; failure of counterparties to perform contractual obligations;
as well as the risk factors described in the Company’s annual information form and other regulatory filings. The forward-looking
statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented
for the purpose of providing information about management's current expectations and plans and allowing investors and others to
obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be
appropriate for other purposes. The Company undertakes no obligations to update or revise such statements to reflect new circumstances
or unanticipated events as they occur, unless required by applicable law.Exhibit 4.15

 

Form 51-102F3

MATERIAL CHANGE REPORT

 

	Item 1.	Name and Address of Reporting Issuer
	 	 
	 	Emerald Health Therapeutics, Inc. (the “Company”)
	 	PO Box 24076, 4420 West Saanich Road
	 	Victoria, British Columbia  V8Z 7E7
	 	 
	Item 2.	Date of Material Change
	 	 
	 	December 7, 2018
	 	 
	Item 3.	News Release
	 	 
	 	A news release was disseminated on December 3, 2018 and December 7, 2018 through GlobeNewswire and subsequently filed on SEDAR. 
	 	 
	Item 4.	Summary of Material Changes
	 	 
	 	On December 3, 2018, the Company announced that it had entered into a binding term sheet with a single Canadian institutional accredited investor (the "Investor") under which the Investor agreed, subject to certain customary conditions, to purchase the common shares of the Company (the "Common Shares") at a price of $2.70 per common share for gross proceeds of $10,800,000 (the "Offering"). 
	 	 
	 	The Company announced that, further to its news release dated December 3, 2018, it had closed the Offering with the Investor. The Investor purchased 4,000,000 Common Shares of the Company at a price of $2.70 per common share for total gross proceeds of $10.8 million. 
	 	 
	 	The Investor has an option to acquire up to a maximum of 1,555,555 additional common shares at a price per common share of $2.70 for a period of ten business days from the closing date.
	 	 
	Item 5.	Full Description of Material Change
	 	 
	 	On December 3, 2018, the Company announced that it had entered into a binding term sheet with the Investor under which the Investor agreed, subject to certain customary conditions, to purchase the Common Shares at a price of $2.70 per common share for gross proceeds of $10,800,000. The Company had the option (the "Option") to increase the Offering by an additional 600,000 common shares. This previously announced Option was increased to 1,555,555 common shares.
	 	 
	 	On December 7, 2018, the Company announced it had closed the Offering. Pursuant to the Offering, the Company issued 4,000,000 Common Shares at a price per common share of $2.70, for gross proceeds of $10.8 million.
	 	 
	 	The Investor may acquire up to a maximum of 1,555,555 additional common shares at a price per common share of $2.70 for a period of ten business days from the closing date. Complete exercise of the Option would add gross proceeds of $4.2 million.

 

     

     

    

 

	 	The Company intends to use the net proceeds of the Offering to fund the completion of capital projects, research and development, working capital, and general corporate purposes.
	 	 
	 	The Common Shares were offered by way of a shelf prospectus supplement filed in all of the provinces of Canada, except Quebec, pursuant to National Instrument 44-101 - Short Form Prospectus Distributions and National Instrument 44-102 Shelf Distributions.
	 	 
	Item 6.	Reliance on subsection 7.1(2) of National Instrument 51-102
	 	 
	 	Not applicable.
	 	 
	Item 7.	Omitted Information
	 	 
	 	Not applicable.
	 	 
	Item 8.	Executive Officer
	 	 
	 	For further information, please contact:
	 	Avtar Dhillon 
	 	President and Executive Chairman
	 	Telephone:  1.800.757.3536 ext.720
	 	 
	Item 9.	Date of Report
	 	 
	 	December 13, 2018

 

    	 	- 2 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}]]